- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Protein Production
- Protein Analytics
- Bioinformatics
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Newsletter: September 2020
Latest Articles and Podcasts
Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform Read More
Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms Read More
The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution. Read More
Facilities and Operations
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States (Cranbury, NJ) Read More
WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in Worcester, MA Read More
WuXi Biologics Completed Acquisition of a Drug Product Manufacturing Facility in Germany Read More
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection Read More
WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility Read More
Resources
Fierce Pharma Virtual Series on COVID-19 Expert Panel Discussion Featuring Chris Chen Read More
Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions Read More
New Flexible Bispecific Antibody Format Demonstrates Improved Therapeutic Properties And Manufacturability Read More
Partner News
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform Read More
WuXi Biologics & Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19 Read More
WuXi Biologics Congratulates Immutep on Positive Interim data for IMP-321 Read More
Awards and Achievements
WuXi Biologics Awarded as “Most Honored Company” by Institutional Investor Read More
WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories Read More
WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform Read More
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?